Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Net Income (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Net Income for 11 consecutive years, with -$92.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 26.69% to -$92.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$411.8 million, a 15.35% increase, with the full-year FY2025 number at -$411.8 million, up 15.35% from a year prior.
  • Net Income was -$92.2 million for Q4 2025 at Intellia Therapeutics, up from -$104.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$46.2 million in Q1 2021 to a low of -$143.7 million in Q1 2022.
  • A 5-year average of -$104.0 million and a median of -$104.2 million in 2022 define the central range for Net Income.
  • Peak YoY movement for Net Income: tumbled 211.02% in 2022, then surged 30.43% in 2023.
  • Intellia Therapeutics' Net Income stood at -$79.9 million in 2021, then tumbled by 31.06% to -$104.7 million in 2022, then dropped by 21.67% to -$127.4 million in 2023, then grew by 1.27% to -$125.8 million in 2024, then increased by 26.69% to -$92.2 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Net Income are -$92.2 million (Q4 2025), -$104.8 million (Q3 2025), and -$102.6 million (Q2 2025).